BR9909731A - Processo para a preparação de n-metil-n[(1s)-1-fenil-2-((3s)-3-hidroxi-pirrolidin-1-il)eti l]-2,2-difenilacetamida enantiomericamente puro - Google Patents

Processo para a preparação de n-metil-n[(1s)-1-fenil-2-((3s)-3-hidroxi-pirrolidin-1-il)eti l]-2,2-difenilacetamida enantiomericamente puro

Info

Publication number
BR9909731A
BR9909731A BR9909731-1A BR9909731A BR9909731A BR 9909731 A BR9909731 A BR 9909731A BR 9909731 A BR9909731 A BR 9909731A BR 9909731 A BR9909731 A BR 9909731A
Authority
BR
Brazil
Prior art keywords
phenyl
methyl
diphenylacetamide
ethyl
preparation
Prior art date
Application number
BR9909731-1A
Other languages
English (en)
Inventor
Karl-August Ackermann
Inge Stein
Rudolf Gottschlich
Bernd Helfert
Andreas Bathe
Jens Budak
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=7865063&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR9909731(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of BR9909731A publication Critical patent/BR9909731A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B35/00—Reactions without formation or introduction of functional groups containing hetero atoms, involving a change in the type of bonding between two carbon atoms already directly linked
    • C07B35/02—Reduction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B43/00—Formation or introduction of functional groups containing nitrogen
    • C07B43/06—Formation or introduction of functional groups containing nitrogen of amide groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/12—Oxygen or sulfur atoms
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pyrrole Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Patente de Invenção: <B>"PROCESSO PARA A PREPARAçãO DE N-METIL-N-[(1S)-1-FENIL-2-((3S)-3-HIDROXIPIRROLIDIN-1-IL)ETI L]-2,2-DIFENILACETAMIDA ENANTIOMERICAMENTE PURO"<D>. A invenção refere-se a um novo processo para a preparação alternativa de N-metil-N-[(1S)-1-fenil-2-((3S)-3-hidroxipirrolidin-1-il)etil]-2,2-difenilacet amida ou N-metil-N-[(1R)-1-fenil-2-((3R)-3-hidroxipirrolidin-1-il)etil]-2,2-difenilace tamida, e os novos compostos N-metil-N-[(1S)-1-fenil-2-((3S)-3-hidroxipirrolidin-1-il)etano] e N-metil-N-[(1R)-1-fenil-2-((3R)-3-hidroxipirrolidin-1-il)etano], que são preparados como intermediários.
BR9909731-1A 1998-04-20 1999-04-16 Processo para a preparação de n-metil-n[(1s)-1-fenil-2-((3s)-3-hidroxi-pirrolidin-1-il)eti l]-2,2-difenilacetamida enantiomericamente puro BR9909731A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19817393 1998-04-20
DE19827633A DE19827633A1 (de) 1998-04-20 1998-06-20 Verfahren zur Herstellung von enantiomerenreinem N-Methyl-N-[(1S)-1-phenyl-2-((3S)-3-hydroxypyrrolidin-1-yl)ethyl]-2,2-diphenylacetamid
PCT/EP1999/002574 WO1999054298A1 (de) 1998-04-20 1999-04-16 Verfahren zur herstellung von enantiomerenreinem n-methyl- n-[(1s)- 1-phenyl- 2-((3s)-3- hydroxypyrrolidin- 1-yl)ethyl]- 2,2- diphenylacetamid

Publications (1)

Publication Number Publication Date
BR9909731A true BR9909731A (pt) 2000-12-19

Family

ID=7865063

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9909731-1A BR9909731A (pt) 1998-04-20 1999-04-16 Processo para a preparação de n-metil-n[(1s)-1-fenil-2-((3s)-3-hidroxi-pirrolidin-1-il)eti l]-2,2-difenilacetamida enantiomericamente puro

Country Status (28)

Country Link
US (1) US6344566B1 (pt)
EP (2) EP1073634B1 (pt)
JP (1) JP4688292B2 (pt)
KR (1) KR100649175B1 (pt)
CN (2) CN1846696A (pt)
AR (2) AR019080A1 (pt)
AT (2) ATE527999T1 (pt)
AU (2) AU761721B2 (pt)
BR (1) BR9909731A (pt)
CA (1) CA2329210C (pt)
CY (1) CY1112314T1 (pt)
CZ (1) CZ301121B6 (pt)
DE (2) DE19827633A1 (pt)
DK (2) DK1073634T3 (pt)
ES (2) ES2375384T3 (pt)
HK (1) HK1039111A1 (pt)
HU (1) HUP0101600A3 (pt)
MY (1) MY120471A (pt)
NO (1) NO317984B1 (pt)
PL (1) PL206969B1 (pt)
PT (1) PT1607090E (pt)
RU (1) RU2298549C2 (pt)
SI (2) SI1607090T1 (pt)
SK (2) SK286442B6 (pt)
TW (1) TWI249524B (pt)
UA (1) UA73472C2 (pt)
WO (1) WO1999054298A1 (pt)
ZA (1) ZA200006689B (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10259245A1 (de) * 2002-12-17 2004-07-01 Merck Patent Gmbh Derivate des Asimadolins mit kovalent gebundenen Säuren
CA2544245A1 (en) * 2003-10-30 2005-05-26 Tioga Pharmaceuticals, Inc. Use of selective opiate receptor modulators in the treatment of neuropathy
US20070160559A1 (en) * 2006-01-12 2007-07-12 Roszell James A Skin disinfectant composition and methods for using
CN101677997B (zh) 2007-03-30 2012-05-09 泰奥加制药公司 用于治疗腹泻型和交替型肠易激综合征的κ-阿片剂激动剂
CN103664727A (zh) * 2013-12-19 2014-03-26 无锡万全医药技术有限公司 一种一锅法制备1-[(3s)-3-羟基吡咯烷-1-基]-(2s)-2-甲氨基-2-苯基乙烷的工艺
CN103772257A (zh) * 2013-12-31 2014-05-07 无锡万全医药技术有限公司 一种制备2-((3s)-3-羟基吡咯烷-1-基)-(1s)-1-苯乙基氨基甲酸酯的方法
EP3277274A4 (en) 2015-04-01 2018-12-05 Cedars-Sinai Medical Center Anti-methanogenic lovastatin analogs or derivatives and uses thereof
CN112574068A (zh) * 2020-11-17 2021-03-30 万华化学（宁波）有限公司 一种低色号高稳定性碳化二亚胺改性异氰酸酯的制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4034785A1 (de) * 1990-11-02 1992-05-07 Merck Patent Gmbh 1-(2-arylethyl)-pyrrolidine
US5232978A (en) * 1988-12-23 1993-08-03 Merck Patent Gesellschaft Mit Beschrankter Haftung 1-(2-arylethyl)-pyrrolidines
DE4215213A1 (de) * 1992-05-09 1993-11-11 Merck Patent Gmbh Arylacetamide
DE4425071C2 (de) * 1994-07-15 1996-08-29 Degussa Verfahren zur Herstellung optisch aktiver Pyrrolidine mit hoher Enantiomerenreinheit
DE19523502A1 (de) * 1995-06-28 1997-01-02 Merck Patent Gmbh Kappa-Opiatagonisten für entzündliche Darmerkrankungen
DE19531464A1 (de) * 1995-08-26 1997-02-27 Merck Patent Gmbh N-Methyl-N-[(1S-)-1-phenyl-2-((3S)-3-hydroxypyrrolidin 1-yl-)-ethyl]-2,2-diphenyl-acetamid
WO1998003491A1 (en) * 1996-07-24 1998-01-29 Warner-Lambert Company Diphenyl-cyclopropenes as selective k-agonists
DE19647538A1 (de) * 1996-11-16 1998-05-20 Merck Patent Gmbh Verfahren zur Herstellung von enantiomerenreinem N-Methyl-N-[1-phenyl-2-(-3-hydroxypyrrolidin-1-yl)ethyl]-2,2-diphenylacetamid

Also Published As

Publication number Publication date
AU2003248428B2 (en) 2005-10-20
EP1607090A1 (de) 2005-12-21
UA73472C2 (en) 2005-08-15
KR100649175B1 (ko) 2006-11-24
CA2329210C (en) 2008-03-04
SI1607090T1 (sl) 2012-01-31
NO20005259D0 (no) 2000-10-19
JP2002512223A (ja) 2002-04-23
DK1607090T3 (da) 2012-01-30
JP4688292B2 (ja) 2011-05-25
TWI249524B (en) 2006-02-21
PL343556A1 (en) 2001-08-27
DE19827633A1 (de) 1999-10-21
ATE527999T1 (de) 2011-10-15
CN1846696A (zh) 2006-10-18
NO20005259L (no) 2000-10-19
AR066455A2 (es) 2009-08-19
PL206969B1 (pl) 2010-10-29
AU761721B2 (en) 2003-06-05
EP1607090B1 (de) 2011-10-12
WO1999054298A1 (de) 1999-10-28
HUP0101600A3 (en) 2002-12-28
CY1112314T1 (el) 2015-12-09
HUP0101600A2 (hu) 2001-09-28
ATE303361T1 (de) 2005-09-15
EP1073634A1 (de) 2001-02-07
EP1073634B1 (de) 2005-08-31
PT1607090E (pt) 2012-01-10
ES2375384T3 (es) 2012-02-29
DK1073634T3 (da) 2006-01-09
RU2298549C2 (ru) 2007-05-10
ZA200006689B (en) 2002-02-18
CN1297435A (zh) 2001-05-30
AU4031199A (en) 1999-11-08
SI1073634T1 (sl) 2006-02-28
CN1310884C (zh) 2007-04-18
CZ301121B6 (cs) 2009-11-11
NO317984B1 (no) 2005-01-17
MY120471A (en) 2005-10-31
SK288016B6 (sk) 2012-11-05
CZ20003860A3 (cs) 2001-01-17
ES2251194T3 (es) 2006-04-16
SK286442B6 (sk) 2008-10-07
KR20010042750A (ko) 2001-05-25
AR019080A1 (es) 2001-12-26
AU2003248428A1 (en) 2003-11-06
HK1039111A1 (en) 2002-04-12
US6344566B1 (en) 2002-02-05
SK15572000A3 (sk) 2001-05-10
CA2329210A1 (en) 1999-10-28
DE59912502D1 (de) 2005-10-06

Similar Documents

Publication Publication Date Title
BR0008815A (pt) Processo para a condensação fracionada de umamistura gasosa do produto, e, coluna deseparação
BR9712285A (pt) Tetrafosfonato bicìclico de trianidridas
BRPI0518489B8 (pt) cloreto de (2r)-dotap enantiomericamente puro, seu uso, e composição farmacêutica
DK1082293T3 (da) Formoterol-polymorfer
PT981529E (pt) Um novo processo para a preparacao de uma substancia farmacologicamente activa
BR9909731A (pt) Processo para a preparação de n-metil-n[(1s)-1-fenil-2-((3s)-3-hidroxi-pirrolidin-1-il)eti l]-2,2-difenilacetamida enantiomericamente puro
BR9804437A (pt) Compostos para a osteoporose
BR9915727A (pt) ésteres derivados de compostos de fenil-ciclohexila substituìdos
BR0111329A (pt) Processo para a preparação de um composto, e, compostos intermediários
DK0751939T3 (da) Naphthylamider som centralnervesystemmidler
BRPI9814894A (pt) processo para a preparação de ácidos 8-metóxi-quinolonocarboxílicos.
PT879228E (pt) Processo para a preparacao de d-treo-(r,r)-metilfenidato e reciclagem de enantiomeros indesejaveis por epimerizacao
BR112012013302A2 (pt) novo processo para a preparação de tapendatol e seus intermediários
PT1237838E (pt) Novo processo
BR0011996A (pt) Preparação de piperidin-4-onas substituìdas
BR0113236A (pt) Processo estereosseletivo para a preparação de butanos (3s,2r)-1-halo-2-hidróxi-3-(protegido)amino-4-substitu ìdos, e, processo para preparação de um composto epóxi
BR9807988A (pt) Processo para a preparação de um composto, e, composto.
DK0804410T3 (da) Fremgangsmåde til fremstilling af retrovirale proteaseinhibitor-mellemprodukter
BR0212390A (pt) Processo para a preparação de cilastatina
MA27004A1 (fr) Conjugues de pregabaline et de lactose
BR0001342A (pt) Processo para a produção de l-aminoácidos por meio de fermentação usando bactérias corineformes
BR9903274A (pt) Processo para isolar vitamina d3
DK0938584T3 (da) Fremgangsmåde til fremstilling af (S)-eller (R)-3,3,3-trifluor-2-hydroxy-2-methylpropionsyre
BR0209842A (pt) Processo para a preparação de imipenem
BR9810472A (pt) Processos para a preparação de (1r,4s)-2-aza-biciclo [2.2.1] hept-5-en-3-ona n-protegida substancialmente enaciomericamente pura e para a resolução enanciomérica de uma mistura racêmica de (±) 2-aza-biciclo [2.2.1] hept-5-en-3-ona n-protegida

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: TIOGA PHARMACEUTICALS, INC. (US)

Free format text: TRANSFERIDO DE: MERCK PATENT GMBH

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: ALTERADA DA INT. CL.: C07D 207/12; C07D 207/09; C07B 43/06; C07B 35/02.

Ipc: C07D 207/12 (2008.04), C07D 207/09 (2008.04), C07B

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 8O E 13 DA LPI.

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.